|
|
Spectrum Pharmaceuticals, Inc. (SPPI) - Financial and Strategic SWOT Analysis Review |
|
Request for Sample Pages |
| Published Date : 11 May 2012 |
|
|
|
Pages : 40 |
|
| |
|
|
|
|
|
|
|
Spectrum Pharmaceuticals, Inc. (Spectrum) is a publicly held bio-pharmaceutical company that is engaged in the development and commercialization of therapeutics targeting various areas like oncology, hematology and urology. The company's products which received FDA approval include Zeavalin and Fusilev. Its product candidate apaziquone is under two phase 3 clinical trials with principal focus on non-muscle invasive bladder cancer. The company is developing apaziquone under the collaboration with Allergan, Inc. The company's another drug known as ozarelix is in phase 2 clinical trials targeting prostatic hypertrophy.
Spectrum Pharmaceuticals, Inc. Key Recent Developments . .
Nov 04, 2010: Spectrum Pharmaceuticals Reports Net Loss Of $4.5 Million For Q3 2010
Nov 03, 2010: Spectrum Receives Nearly $1 Million In Grants For Qualifying Therapeutic Discovery Projects
Oct 12, 2010: Spectrum Appoints Brett Scott As Senior Vice President And Acting CFO
Aug 09, 2010: Spectrum Reports Net Loss Of $9.7 Million For Q2 2010
Jul 19, 2010: Spectrum Appoints George Tidmarsh As Senior Vice President & Chief Scientific Officer
This comprehensive SWOT profile of Spectrum Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including,
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. |
|
|
|
Table of Contents : |
2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Spectrum Pharmaceuticals, Inc. - Key Facts 5
Spectrum Pharmaceuticals, Inc. - Key Employees 6
Spectrum Pharmaceuticals, Inc. - Key Employee Biographies 7
Spectrum Pharmaceuticals, Inc. - Major Products and Services 8
Spectrum Pharmaceuticals, Inc. - History 9
Spectrum Pharmaceuticals, Inc. - Company Statement 11
Spectrum Pharmaceuticals, Inc. - Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Spectrum Pharmaceuticals, Inc. - Business Description 14
Spectrum Pharmaceuticals, Inc. - SWOT Analysis 15
SWOT Analysis - Overview 15
Spectrum Pharmaceuticals, Inc. - Strengths 15
Strength - Fusilev, Belinostat -Orphan Drug Designation 15
Strength - Broad Product Portfolio 15
Strength - Expanding Market Share in Sector 15
Strength - Patents and Proprietary Technology Portfolio 15
Spectrum Pharmaceuticals, Inc. - Weaknesses 16
Weakness - Negative Margins 16
Weakness - Limited Liquidity Position 16
Weakness - Limited Number of Customers 16
Spectrum Pharmaceuticals, Inc. - Opportunities 16
Opportunity - Strategic Alliances 16
Opportunity - Emerging Markets 17
Opportunity - Growing Oncology Market 17
Spectrum Pharmaceuticals, Inc. - Threats 17
Threat - Acting Guarantor of RIT 17
Threat - Intense Competition 17
Threat - Tightening of the FDA’s Regulatory Oversight 18
Threat - Uncertain R&D Outcomes 18
Spectrum Pharmaceuticals, Inc. - Key Competitors 19
Section 3 – Company Financial Ratios 20
Financial Ratios - Capital Market Ratios 20
Financial Ratios - Annual Ratios 20
Performance Chart 22
Financial Performance 22
Financial Ratios - Interim Ratios 23
Financial Ratios - Ratio Charts 24
Section 4 – Company’s Recent Developments 25
Oct 12, 2010: Spectrum Appoints Brett Scott As Senior Vice President And Acting CFO 25
Aug 09, 2010: Spectrum Reports Net Loss Of $9.7 Million For Q2 2010 25
Jul 19, 2010: Spectrum Appoints George Tidmarsh As Senior Vice President & Chief Scientific Officer 26
Jul 16, 2010: Spectrum Appoints Kevin Splaine As COO For Spectrum Health Grand Rapids 26
Jun 23, 2010: Spectrum Pharmaceuticals Appoints James Shields As Chief Commercial Officer 27
May 10, 2010: Spectrum Reports Net Loss Of $39 Million For Q1 2010 27
Apr 21, 2010: Spectrum Announces Belinostat Data Presentation At AACR 28
Apr 05, 2010: Spectrum Pharmaceuticals Q4 Total Revenues Up 29
Feb 02, 2010: Spectrum Pharmaceuticals Licenses Belinostat From TopoTarget 29
Jan 29, 2010: Spectrum Receives $16m From Collaboration Agreement For Apaziquone 30
Section 5 – Appendix 31
Methodology 31
Ratio Definitions 31
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Tables
Spectrum Pharmaceuticals, Inc., Key Facts 5
Spectrum Pharmaceuticals, Inc., Key Employees 6
Spectrum Pharmaceuticals, Inc., Key Employee Biographies 7
Spectrum Pharmaceuticals, Inc., Major Products and Services 8
Spectrum Pharmaceuticals, Inc., History 9
Spectrum Pharmaceuticals, Inc., Subsidiaries 13
Spectrum Pharmaceuticals, Inc., Key Competitors 19
Spectrum Pharmaceuticals, Inc., Ratios based on current share price 20
Spectrum Pharmaceuticals, Inc., Annual Ratios 20
Spectrum Pharmaceuticals, Inc., Interim Ratios 23
Currency Codes 31
Capital Market Ratios 31
Equity Ratios 32
Profitability Ratios 32
Cost Ratios 33
Liquidity Ratios 33
Leverage Ratios 34
Efficiency Ratios 34
List of Figures
Spectrum Pharmaceuticals, Inc., Performance Chart (2005 - 2009) 22
Spectrum Pharmaceuticals, Inc., Ratio Charts 24 |
|
|
|
Published By : GlobalData |
|
|
Category
Related Report:
Automotive,
Automobile,
Aerospace & Aviation,
Banking,
Consumer Goods,
Construction,
Chemicals,
Defense,
Diabetes,
Disease,
Drinks,
Energy,
Electronics,
Financial
,
Food & Drinks,
Glass,
Healthcare,
Insurance,
Information technology,
Investment,
Industrial Gases,
Industry Profile,
Medical,
Media,
Marketing,
Miscellaneous,
Metals & Mining,
Nuclear Energy,
Oil & Gas,
Power,
Real Estate,
Software,
Solar,
Transportation
|
|
|
|
